2023
2510. Adapting the CDC HCV viral clearance cascade methodology for persons with HIV (PWH) and HCV co-infection in 5 Health Department Jurisdictions in the US
Wegener M, Brooks R, Nichols L, Villanueva M. 2510. Adapting the CDC HCV viral clearance cascade methodology for persons with HIV (PWH) and HCV co-infection in 5 Health Department Jurisdictions in the US. Open Forum Infectious Diseases 2023, 10: ofad500.2128. PMCID: PMC10678948, DOI: 10.1093/ofid/ofad500.2128.Peer-Reviewed Original ResearchHCV surveillance dataPrevalent HIVRecent HCVViral clearanceViral testingHealth jurisdictionsInitial infectionHIV transmission risk factorsHIV/HCV coinfectionUndetectable HIV viral loadSurveillance dataHCV cure ratesHCV test resultsHCV viral clearanceHealth department jurisdictionsHIV viral loadHIV/HCVCo-infected populationTransmission risk factorsCoinfected populationHCV cascadeHCV coinfectionHCV microeliminationHCV clearanceHIV careImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersCreating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods
Brooks R, Wegener M, Speers S, Nichols L, Sideleau R, Valeriano T, Buchelli M, Villanueva M. Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods. Health Promotion Practice 2023, 24: 1039-1049. PMID: 37439600, DOI: 10.1177/15248399231169792.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHepatitis C virusSVR ratesHCV treatmentHIV clinicTreatment cascadeTreatment statusSustained virologic response ratesHCV care cascadeHCV treatment cascadeHCV treatment statusVirologic response ratesHIV viral suppressionPatient treatment statusPublic health approachCare cascadeHepatitis CViral suppressionActing antiviralsTreatment initiationC virusResponse rateClinical staffCoinfectionCharacterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels
Zhao A, Wegener M, Brooks R, Mininberg L, Helou E, Maughan A, Villanueva M. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels. Health Promotion Practice 2023, 24: 1029-1038. PMID: 37439687, DOI: 10.1177/15248399231169793.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHepatitis C virusHCV coinfectionHIV clinicDirect-acting antiviral medicationsHIV transmission risk factorsPrimary care HIV clinicClinic-level barriersHCV elimination targetsChronic HCV infectionRetrospective chart reviewPatient-level barriersClinical practice patternsMedication-Assisted TreatmentTransmission risk factorsIllicit substance usePatient-specific issuesLack of transportationSubstance use problemsMental health issuesHCV cureHCV infectionHCV treatmentHepatitis CUntreated patientsImplementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut
Wegener M, Brooks R, Speers S, Nichols L, Villanueva M. Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut. Public Health Reports 2023, 139: 208-217. PMID: 37232422, PMCID: PMC10851907, DOI: 10.1177/00333549231172173.Peer-Reviewed Original ResearchHIV viral loadHCV coinfectionViral loadSurveillance databaseUndetectable HIV viral loadDetectable HIV viral loadDisease controlHIV/AIDS Reporting SystemHCV elimination strategyRecent HIV testAIDS Reporting SystemElectronic Disease Surveillance SystemOutcomes of peoplePublic health departmentsDisease surveillance systemsSurveillance-based approachHCV cureHCV statusHepatitis CAntiviral medicationsHIV testC virusViral testingHealth departmentsInitial infection
2022
Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study
Jia J, Zhu Q, Deng L, Lan G, Johnson A, Chen H, Shen Z, Li J, Xing H, Ruan Y, Li J, Lu H, Vermund SH, Zhu J, Qian HZ. Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China: an observational cohort study. Infectious Diseases Of Poverty 2022, 11: 7. PMID: 34986877, PMCID: PMC8734096, DOI: 10.1186/s40249-021-00921-5.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusAntiretroviral therapyHigh mortalityHCV coinfectionC virusNational Free Antiretroviral Treatment ProgramHBV co-infected patientsHBV/HCV coinfectionRetrospective cohort study analysisEffect of ARTCohort study analysisObservational cohort studyAntiretroviral treatment programOverall mortality rateProportional hazards modelTreatment attrition rateCause deathHCV-coHIV patientsBaseline infectionCohort studyHBV-HCVHepatitis BHepatitis treatment
2019
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection
Hanberg JS, Freiberg MS, Goetz MB, Rodriguez-Barradas MC, Gibert C, Oursler KA, Justice AC, Tate JP. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection. Open Forum Infectious Diseases 2019, 6: ofz347. PMID: 31660334, PMCID: PMC6786514, DOI: 10.1093/ofid/ofz347.Peer-Reviewed Original ResearchHuman immunodeficiency virusVACS Index 2.0Veterans Aging Cohort StudyAddition of NLRHepatic decompensationLymphocyte ratioHepatitis C virusInflammatory biomarkersImmunodeficiency virusHepatitis C virus statusHIV/HCV coinfectionC virus statusPrognostic inflammatory biomarkerSoluble CD-14Strong unadjusted associationsAging Cohort StudyBiomarkers of inflammationPoor health outcomesMortality risk indexHCV coinfectionAntiretroviral therapyCohort studyBiomarker cohortD-dimerPrognostic index
2017
A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease
Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Maziak W. A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease. Reviews In Medical Virology 2017, 28 PMID: 29135056, DOI: 10.1002/rmv.1953.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionCarotid intima-media thicknessHuman immunodeficiency virusC-reactive proteinHCV coinfectionHealthy controlsCoinfected individualsCVD biomarkersEndothelial markersHepatitis C virus coinfectionBiomarkers of CVDC virus coinfectionCardiovascular disease riskIntima-media thicknessSignificant lower levelsWeb of ScienceHCV monoinfectionCVD riskVirus coinfectionImmunodeficiency virusProspective studyIL-6Clinical trialsCardiovascular diseaseCarotid plaquesRisk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV-/HCV-coinfected patientsHIV/HCV coinfectionVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injuryHIV/HCV coinfection and the risk of cardiovascular disease: A meta‐analysis
Osibogun O, Ogunmoroti O, Michos E, Spatz E, Olubajo B, Nasir K, Madhivanan P, Maziak W. HIV/HCV coinfection and the risk of cardiovascular disease: A meta‐analysis. Journal Of Viral Hepatitis 2017, 24: 998-1004. PMID: 28502092, DOI: 10.1111/jvh.12725.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHazard ratioCardiovascular diseaseHIV monoinfectionCVD riskHepatitis C virus coinfectionTraditional CVD risk factorsC virus coinfectionImproved antiretroviral therapyAdjusted hazard ratioCVD risk factorsRisk reduction therapyCongestive heart failureCoronary artery diseaseHuman immunodeficiency virusIncreased inflammatory responseRandom-effects modelWeb of ScienceHCV individualsAntiretroviral therapyCohort studyCVD outcomesArtery diseaseHeart failure
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete data
2013
The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
Morano JP, Gibson BA, Altice FL. The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLOS ONE 2013, 8: e64321. PMID: 23691197, PMCID: PMC3653872, DOI: 10.1371/journal.pone.0064321.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHIV monoinfectionTransmission risk behaviorsCross-sectional studyMobile medical clinicViral infection statusCrack cocaine useHCV monoinfectionHCV infectionIndependent correlatesCoinfection statusLifetime HIVClinical careHCVHIVMonoinfectionElectronic databasesDisease preventionCocaine useMedical clinicsRisk behaviorsGallery useInfection statusCoinfectionAn internationally generalizable risk index for mortality after one year of antiretroviral therapy
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27: 563-572. PMID: 23095314, PMCID: PMC4283204, DOI: 10.1097/qad.0b013e32835b8c7f.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesEuropeFemaleHemoglobinsHepatitis CHIV InfectionsHumansMaleMiddle AgedMultiple Organ FailurePlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralUnited StatesConceptsHIV-1 RNAVeterans Aging Cohort StudyMultiorgan system injuryCD4 cell countAntiretroviral therapyVACS IndexSystem injuryCell countDetectable HIV-1 RNAART Cohort CollaborationOutcome of deathAging Cohort StudyHepatitis C statusMortality risk indexGood discriminationART initiationCohort CollaborationHCV coinfectionCohort studyHIV deathsHIV markersHIV infectionValidation cohortAlanine transaminaseExcess mortality
2009
HIV infection and the risk of diabetes mellitus
Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC. HIV infection and the risk of diabetes mellitus. AIDS 2009, 23: 1227-1234. PMID: 19444074, PMCID: PMC2752953, DOI: 10.1097/qad.0b013e32832bd7af.Peer-Reviewed Original ResearchConceptsRisk of diabetesHCV coinfectionHIV infectionUninfected veteransDiabetes mellitusRisk factorsVeterans Aging Cohort StudyMinority raceDiabetes mellitus differsPrevalent diabetes mellitusOdds of diabetesAging Cohort StudyCohort studyInhibitor therapyHIV statusUninfected personsLower BMIMale sexBaseline prevalenceARV treatmentOdds ratioHigh riskLow prevalenceHIVLower risk
2004
Risk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection
Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection. Hepatology 2004, 40: 115-119. PMID: 15239093, DOI: 10.1002/hep.20289.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusPre-HAART eraHAART eraRisk of diabetesHCV coinfectionHCV infectionHigh riskHepatitis C virus infectionMultivariate Cox regression analysisVeterans Affairs administrative databasesActive antiretroviral therapyC virus infectionCox regression analysisIncidence of diabetesKaplan-Meier curvesCox regression methodsDiagnosis of diabetesHCV-HIVAntiretroviral therapyHazard ratioLiver diseaseImmunodeficiency virusAdministrative databasesVirus infectionDrug diagnoses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply